Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of AMT-126 in Healthy Volunteers
NCT05476107Phase 1Completed
- Sponsor
- Applied Molecular Transport
- Start
- Feb 2021
- Primary completion
- Mar 2022
- Modality
- Gene Editing, Gene Silencing, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AMT-126 in ulcerative colitis (UC) (3 arms), sponsored by Applied Molecular Transport. Primary endpoints: Incidence of Treatment-emergent adverse events at 5 days and In vivo performance of an AMT-126 tablet formulation at 5 days. Started Feb 2021; status: completed.
02
Drugs
AMT-126
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05476107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476107.